These studies were undertaken because primary and acquired resistance to both agents could be overcome, their partly non-overlapping mechanisms of action, and the well-characterized synergistic interaction between them could be expected in patients with HER2+ breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.